tetracycline and chloroquine-diphosphate

Topics: Amebicides; Antimalarials; Antiprotozoal Agents; Balantidiasis; Chloroquine; Coccidiosis; Dientamoebiasis; Drug Combinations; Dysentery, Amebic; Emetine; Furans; Furazolidone; Giardiasis; Humans; Intestinal Diseases, Parasitic; Iodoquinol; Liver Abscess, Amebic; Metronidazole; Paromomycin; Quinacrine; Sulfamethoxazole; Tetracycline; Tinidazole; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination

The objective of this study was to evaluate the feasibility of 10 commonly used active pharmaceutical ingredients (APIs) compounded in oral suspensions using an internationally used suspending vehicle (SyrSpend(®) SF PH4 liquid): (i) amlodipine, (as besylate) 1.0mg/mL; (ii) chloroquine phosphate,15.0 mg/mL; (iii) dapsone, 2.0 mg/mL; (iv) phenytoin, 15.0 mg/mL; (v) pyridoxine hydrochloride, 50.0 mg/mL; (vi) sulfadiazine, 100.0 mg/mL; (vii) sulfasalazine, 100.0 mg/mL; (viii) tetracycline hydrochloride, 25.0 mg/mL; (ix) trimethoprim, 10.0 mg/mL; and (x) zonisamide, 10.0 mg/mL. All suspensions were stored both at controlled refrigeration (2-8 °C) and controlled room temperature (20-25 °C). Feasibility was assessed by measuring the percent recovery at varying time points throughout a 90-day period. API quantification was performed by high-performance liquid chromatography (HPLC-UV), via a stability-indicating method. Given the percentage of recovery of the APIs within the suspensions, the expiration date of the final products (API+vehicle) was at least 90 days for all suspensions with regard to both the controlled temperatures. This suggests that the vehicle is stable for compounding APIs from different pharmacological classes.

Topics: Administration, Oral; Amlodipine; Chloroquine; Chromatography, High Pressure Liquid; Dapsone; Drug Stability; Drug Storage; Feasibility Studies; Hydrogen-Ion Concentration; Isoxazoles; Phenytoin; Pyridoxine; Sulfadiazine; Sulfasalazine; Suspensions; Tetracycline; Trimethoprim; Zonisamide